2026-05-17T05:52:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/236702024-10-09T06:35:00Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Arias-Fernández, María author Fresneda, Sergio author Abbate, Manuela author Torres-Carballo, Marina author Huguet-Torres, Aina author Sánchez-Rodríguez, Cristian author Bennasar-Veny, Miquel author Yañez, Aina M author Busquets-Cortés, Carla author 2023-04-07 Non-alcoholic fatty liver disease (NAFLD) is a global health problem associated with liver morbimortality, obesity, and type 2 diabetes mellitus. This study aimed to analyze the prevalence of NAFLD (defined as a fatty liver index [FLI] ≥ 60) and its association with other cardiovascular risk (CVR) factors in patients with prediabetes and overweight/obesity. The present cross-sectional analysis uses baseline data from an ongoing randomized clinical trial. Sociodemographic and anthropometric characteristics, CVR (assessed by the REGICOR-Framingham risk equation), metabolic syndrome (MetS), and FLI-defined NAFLD (cut-off value of ≥60) were assessed. The prevalence of FLI-defined NAFLD was 78% overall. Men exhibited a worse cardiometabolic profile as compared to women, specifically, with higher values of systolic blood pressure (137.02 ± 13.48 vs. 131.22 ± 14.77 mmHg), diastolic blood pressure (85.33 ± 9.27 vs. 82.3 ± 9.12 mmHg), aspartate aminotransferase (AST) (27.23 ± 12.15 vs. 21.23 ± 10.05 IU/L), alanine aminotransferase (ALT) (34.03 ± 23.31 vs. 21.73 ± 10.80 IU/L), and higher CVR (5.58 ± 3.16 vs. 3.60 ± 1.68). FLI-defined NAFLD was associated with elevated AST, ALT, and the presence of MetS (73.7%) and CVR for the whole sample. People with prediabetes present a high burden of comorbidities related to CVR, despite clinical follow-up, and it is recommended to actively begin working with them to reduce their risks. Arias-Fernández M, Fresneda S, Abbate M, Torres-Carballo M, Huguet-Torres A, Sánchez-Rodríguez C, et al. Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity. Metabolites. 2023 Apr 7;13(4). 10.3390/metabo13040531 2218-1989 Metabolites https://hdl.handle.net/20.500.13003/19002 37110189 L2022890483 https://hdl.handle.net/20.500.12105/23670 979024900001 Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity